Detection of abnormal glucose tolerance in Africans is improved by combining A1c with fasting glucose: The Africans in America study

Diabetes Care

Volumn 38, Issue 2, 2015, Pages 213-219

  Sumner, Anne E ^a   Thoreson, Caroline K ^a   O'Connor, Michelle Y ^a   Ricks, Madia ^a   Chung, Stephanie T ^a   Tulloch Reid, Marshall K ^b   Lozier, Jay N ^c   Sacks, David B ^c  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF THE WEST INDIES   (Jamaica)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AFRICAN; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEMOGLOBIN DETERMINATION; HUMAN; IMMIGRANT; IMPAIRED GLUCOSE TOLERANCE; INTERMETHOD COMPARISON; MALE; ORAL GLUCOSE TOLERANCE TEST; SENSITIVITY AND SPECIFICITY; UNITED STATES; AFRICA; BLOOD; DIET RESTRICTION; ETHNOLOGY; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AFRICA; BLOOD GLUCOSE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FASTING; FEMALE; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

EID: 84921932495     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-1179     Document Type: Article

References (34)

1. International Diabetes Federation. IDF Diabetes Atlas. 6th ed. Brussels, International Diabetes Federation, 2013
2. Summary of revisions for the 2010 Clinical Practice Recommendations. Diabetes Care 2010;33(Suppl.1):S3
3. Di Pino A, Scicali R, Calanna S, et al. Cardiovascular risk profile in subjects with prediabetes and new-onset type 2 diabetes identified by HbA (1c) according to American Diabetes Association criteria. Diabetes Care 2014;37:1447-1453
4. Lorenzo C, Wagenknecht LE, Hanley AJ, Rewers MJ, Karter AJ, Haffner SM. A1C between 5.7 and 6.4% as a marker for identifying prediabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care 2010;33:2104-2109
5. Piel FB, Howes RE, Patil AP, et al. The distribution of haemoglobin C and its prevalence in newborns in Africa. Sci Rep 2013;3:1671
6. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2013;381:142-151
7. Allison AC. The distribution of the sickle-cell trait in East Africa and elsewhere, and its apparent relationship to the incidence of subtertian malaria. Trans R Soc Trop Med Hyg 1954;48:312-318
8. Hanchard NA, Hambleton I, Harding RM, McKenzie CA. The frequency of the sickle allele in Jamaica has not declined over the last 22 years. Br J Haematol 2005;130:939-942
9. Meyer LM, Adams JG 3rd, Steinberg MH, Miller IE, Stokes N. Screening for sickle cell trait: the Veterans Administration National Sickle Cell Program. Am J Hematol 1987;24:429-432
10. Taylor C, Kavanagh P, Zuckerman B. Sickle cell traitdneglected opportunities in the era of genomic medicine. JAMA 2014;311:1495-1496
11. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197
12. Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care 2011;34:518-523
13. Little RR, Rohlfing CL, Sacks DB; National Glycohemoglobin Standardization Program (NGSP) Steering Committee. Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care. Clin Chem 2011;57:205-214
14. Bianchi C, Miccoli R, Bonadonna RC, et al.; GENFIEV Investigators. Pathogenetic mechanisms and cardiovascular risk: differences between HbA (1c) and oral glucose tolerance test for the diagnosis of glucose tolerance. Diabetes Care 2012;35:2607-2612
15. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U. S. population in 1988-2006. Diabetes Care 2010;33:562-568
16. Olson DE, Rhee MK, Herrick K, Ziemer DC, Twombly JG, Phillips LS. Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. Diabetes Care 2010;33:2184-2189
17. O'Connor MY, Thoreson CK, Ricks M, et al. Worse cardiometabolic health in African immigrant men than African American men: reconsideration of the healthy immigrant effect. Metab Syndr Relat Disord 2014;12:347-353
18. Ukegbu UJ, Castillo DC, Knight MG, et al. Metabolic syndrome does not detect metabolic risk in African men living in the U. S. Diabetes Care 2011;34:2297-2299
19. Yu SS, Ramsey NL, Castillo DC, Ricks M, Sumner AE. Triglyceride-based screening tests fail to recognize cardiometabolic disease in African immigrant and African-American men. Metab Syndr Relat Disord 2013;11:15-20
20. American Diabetes Association. Executive summary: Standards of medical care in diabetesd2014. Diabetes Care 2014;37(Suppl. 1):S5-S13
21. Sumner AE, Luercio MF, Frempong BA, et al. Validity of the reduced-sample insulin modified frequently-sampled intravenous glucose tolerance test using the nonlinear regression approach. Metabolism 2009;58:220-225
22. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN. MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 2003;5:1003-1015
23. NGSP. HbA1c assay interferences. Available from http://www.ngsp.org/interf.asp. Accessed 8 May 2014
24. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U. S. population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 2006;29:1263-1268
25. Guerrero R, Vega GL, Grundy SM, Browning JD. Ethnic differences in hepatic steatosis: an insulin resistance paradox? Hepatology 2009;49:791-801
26. McCurdy PR. 32-DFP and 51-Cr for measurement of red cell life span in abnormal hemoglobin syndromes. Blood 1969;33:214-224
27. Prindle KH Jr, McCurdy PR. Red cell lifespan in hemoglobin C disorders (with special reference to hemoglobin C trait). Blood 1970;36:14-19
28. Bry L, Chen PC, Sacks DB. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001;47:153-163
29. Little RR, Sacks DB. HbA1c: how do we measure it and what does it mean? Curr Opin Endocrinol Diabetes Obes 2009;16:113-118
30. John W, Little RR, Sacks DB, et al. Multicentre evaluation of the Premier Hb9210 HbA1c analyser. Clin Chem Lab Med 2 Oct. 2014 [Epub ahead of print]
31. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
32. Li G, Zhang P, Wang J, et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study. Lancet Diabetes Endocrinol 2014;2:474-480
33. Lindström J, Ilanne-Parikka P, Peltonen M, et al.; Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-1679
34. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990;263:2893-2898